MTOR and cancer: The miR-223 is an anti-inflammatory miRNA that in cancer acts either as an oncosuppressor or oncopromoter, in a context-dependent manner68, whereas in breast cancer, they dampened the activation of the EGF-associated cancerous pathway69. Such increased expression, especially by the combined ProE-NLC + 5-FU, was associated with decreased breast cancer cell proliferation and apoptosis, demonstrated as decreased mTOR expression and increased p53 expression.